BioMaxima

BioMaxima Cash Flow per Share

The Operating Cash Flow per Share of BioMaxima (BMX.WA) as of Oct 16, 2026 is 0.56 PLN. In the previous year, Operating Cash Flow per Share was -0.04 PLN — a change of -1,636.84% (higher).

Cash Flow per Share

0.56PLN

YoY

-1,636.84%

Last updated:

Operating Cash Flow per Share of BioMaxima is 2025 0.56 PLN. Operating Cash Flow per Share of BioMaxima was 2024 -0.04 PLN. It decreases by -1,636.84% higher compared to the previous year.

The BioMaxima Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
0.57 PLN
Jan 1, 2019
1.17 PLN
Jan 1, 2020
0.89 PLN
Jan 1, 2021
-0.03 PLN
Jan 1, 2022
8.31 PLN
Jan 1, 2023
0.38 PLN
Jan 1, 2024
-0.04 PLN
Jan 1, 2025
0.56 PLN
The BioMaxima Cash Flow per Share history
YEARCash Flow per ShareYoY
0.56PLN-1,636.84%
-0.04PLN-109.55%
0.38PLN-95.43%
8.31PLN-28,155.61%
-0.03PLN-103.34%
0.89PLN-24.27%
1.17PLN+105.92%
0.57PLN+15.27%
0.49PLN+27.81%
0.39PLN-48.71%
0.75PLN+307.63%
0.18PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMaxima stock

Operating Cash Flow per Share of BioMaxima is 0.56 PLN in 2025.

Operating Cash Flow per Share of BioMaxima changed from -0.04 PLN to 0.56 PLN, representing a -1,636.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share BioMaxima since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — BioMaxima

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — BioMaxima